

In the claims:

1. (Amended) A tissue scaffold implant device, comprising:

a foam tissue scaffold component having a pore structure effective to facilitate tissue infiltration and growth into the foam tissue scaffold component; and

a fixation component comprising scaffold support means for supporting said foam tissue scaffold component and anchor means,

wherein the foam tissue scaffold component is fixedly attached to the scaffold fixation component via partial encapsulation of the fixation component by the foam tissue scaffold component.

2. (Amended) The device of claim 1 wherein ~~the fixation component comprises tissue scaffold support means and anchor means and~~ the foam tissue scaffold component substantially encapsulates the ~~tissue~~ scaffold support means.

3. (Amended) The device of claim 1 wherein the foam tissue scaffold component comprises a lyophilized polymer.

4. (Original) The device of claim 3 wherein the lyophilized polymer is bioabsorbable.

5. (Original) The device of claim 4 wherein the fixation component comprises a bioabsorbable polymer.

6. (Original) The device of claim 4 wherein the fixation component comprises a non-bioabsorbable polymer.

7. (Amended) The device of claim 5 wherein the lyophilized bioabsorbable polymer is selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylene oxalates, polyamides, tyrosine-derived polycarbonates, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes and biopolymers.

8. (Original) The device of claim 7 wherein the aliphatic polyesters are selected from the group consisting of homopolymers and copolymers of lactide, glycolide, ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one, 2,5-diketomorpholine, pivalolactone, α,α-diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione and 6,8-dioxabicyclooctane-7-one.

9. (Original) The device of claim 8 wherein the aliphatic polyesters are elastomeric.

B, 10. (Amended) The device of claim 7 wherein the lyophilized biopolymers are selected from the group consisting of hyaluronic acid, collagen, recombinant collagen, cellulose, elastin, alginates, chondroitin sulfate, chitosan, chitin, keratin and silk.

11. (Original) The device of claim 1 wherein the pore structure is open-cell.

12. (Original) The device of claim 1 wherein the pores have an average diameter of from about 10 to about 1,000 microns.

13. (Amended) The device of claim 2 wherein the scaffold support means comprises through-holes.

14. (Original) The device of claim 1 further comprising a reinforcing component.

Claims 15-22 canceled.